Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Free Report) rose 5.2% on Thursday . The company traded as high as $2.37 and last traded at $1.42. Approximately 76,088,712 shares traded hands during mid-day trading, an increase of 6,629% from the average daily volume of 1,130,804 shares. The stock had previously closed at $1.35.
Dermata Therapeutics Price Performance
The firm has a 50-day moving average of $1.21 and a 200-day moving average of $1.31. The stock has a market cap of $2.90 million, a PE ratio of -0.09 and a beta of 0.65.
About Dermata Therapeutics
Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
Read More
- Five stocks we like better than Dermata Therapeutics
- Dividend Payout Ratio Calculator
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- Trading Stocks: RSI and Why it’s Useful
- Top 3 Beverage Stocks Pouring Out Profits
- How is Compound Interest Calculated?
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
